Bladder cancer
UPDATED --- New hope for patients progressing after prior treatment for mUCaHervé (68 years old)
After retiring from his job as a colour chemist in a paint factory, Hervé, 68 years old, spends his days painting vibrant murals. His talent for creating colours continues to brighten his community.
He initially presented with UCa of the bladder with lung metastases and was treated with enfortumab vedotin + pembrolizumab. After 17 cycles of treatment, he has now progressive disease.
Assessment summary:
- ECOG PS: 0
- Peripheral neuropathy: grade 1
- No hearing impairment
- GFR: 60 ml/min
- CT scan reveals worsening of lung and new bone metastases
- FGFR2/3 alteration status in metastatic biopsy specimen: wild type